Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Background: Treatment of cancers with programmed cell death protein 1 (PD-1) pathway inhibitors can lead to immune-related adverse events (irAEs), which could be serious and even fetal. Therefore, clinicians should be aware of the characteristics of irAEs associated with the use of such drugs. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peng-Fei, Chen, Yang, Song, Si-Ying, Wang, Ting-Jian, Ji, Wen-Jun, Li, Shou-Wei, Liu, Ning, Yan, Chang-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651530/
https://www.ncbi.nlm.nih.gov/pubmed/29093678
http://dx.doi.org/10.3389/fphar.2017.00730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651530/
https://www.ncbi.nlm.nih.gov/pubmed/29093678
http://dx.doi.org/10.3389/fphar.2017.00730

Ejemplares similares